Eastgate Biotech Corp.
ETBI
$0.00
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | 03/31/2017 | 12/31/2016 | 09/30/2016 | |
|---|---|---|---|---|---|
| Revenue | 46.54% | -29.75% | -30.50% | -29.09% | -28.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.54% | -29.75% | -30.50% | -29.09% | -28.70% |
| Cost of Revenue | 49,833.33% | 426.85% | -- | -- | -101.54% |
| Gross Profit | -2,033.33% | -8.13% | -- | -- | -99.47% |
| SG&A Expenses | 37.78% | -28.32% | -39.07% | -32.67% | -31.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.99% | -26.48% | -38.99% | -38.80% | -36.15% |
| Operating Income | -25.26% | 28.33% | 36.78% | 36.87% | 34.25% |
| Income Before Tax | -19.64% | 24.66% | 37.60% | 30.46% | 28.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.64% | 24.66% | 37.60% | 30.46% | 28.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.64% | 24.66% | 37.60% | 30.46% | 28.35% |
| EBIT | -25.26% | 28.33% | 36.78% | 36.87% | 34.25% |
| EBITDA | 22.41% | 71.05% | 62.49% | 37.50% | 34.89% |
| EPS Basic | 30.56% | 42.75% | 53.85% | 65.72% | 73.46% |
| Normalized Basic EPS | 26.15% | 37.97% | 50.00% | 66.67% | 74.51% |
| EPS Diluted | 30.56% | 42.75% | 53.85% | 65.72% | 73.46% |
| Normalized Diluted EPS | 26.15% | 37.97% | 50.00% | 66.67% | 74.51% |
| Average Basic Shares Outstanding | 93.69% | 36.37% | 29.94% | 59.34% | 116.52% |
| Average Diluted Shares Outstanding | 93.69% | 36.37% | 29.94% | 59.34% | 116.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |